Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands

#514

Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.

Aim(s): This study evaluated the cost-effectiveness of SU + best supportive care (BSC) compared with placebo + BSC in pts with pNET from the Dutch payer perspective.

Materials and methods: A Markov model was developed to predict life years (LYs) gained, quality-adjusted life-years (QALYs) gained, and associated costs of pNET treatment over pts' lifetimes. The model tracked transitions of pts between three health states: progression-free, post-progression, and death. Transition probabilities and adverse event (AE) rates were based on published results of the phase III pNET trial of SU. Resource use for BSC and AE management was estimated by Dutch clinical experts. Costs and effects were discounted at 4% and 1.5%, respectively.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kansal A, Chao R, Patyna S, Scheijbeler H, Klok R,

Keywords: pancreatic NET, Sunitinib, overall survival, cost-effectiveness,